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Abstract
Cystic fibrosis (CF) is the most common lethal inherited dis-
ease in the Caucasian population with an incidence of - 1 in
2,500 live births. Pulmonary complications of CF, which are
the most morbid aspects of the disease, are caused by primary
abnormalities in epithelial cells that lead to impaired mucocili-
ary clearance. One potential therapeutic strategy is to reconsti-
tute expression of the CF gene in airway epithelia by somatic
gene transfer. To this end, we have developed an animal model
of the human airway using bronchial xenografts and have tested
the efficiency of in vivo retroviral gene transfer. Using the LacZ
reporter gene, we find the efficiency of in vivo retroviral gene
transfer to be dramatically dependent on the regenerative and
mitotic state of the epithelium. Within an undifferentiated re-
generating epithelium in which 40% of nuclei labeled with
BrdU, 5-10% retroviral gene transfer was obtained. In con-
trast, no gene transfer was noted in a fully differentiated epithe-
lium in which 1% of nuclei labeled with BrdU. These findings
suggest that retroviral mediated gene transfer to the airway in
vivo may be feasible if the proper regenerative state can be
induced. (J. Clin. Invest. 1992. 90:2598-2607.) Key words:
gene therapy * cystic fibrosis * recombinant retroviruses * air-
way epithelial cells * gene transfer
Introduction
Cystic fibrosis (CF)' is an inherited disease that affects several
organ systems. The pulmonary manifestations of CF, which
are believed to be caused by defects in mucociliary clearance,
are the most morbid manifestations ofthe disease (1). Isolation
of the gene responsible for CF suggested possible therapeutic
strategies based on lung-directed somatic gene transfer (2, 3, 4).
Functional correction ofthe defect in cultured CF cells by viral
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1. Abbreviations used in this paper: BrdU, 5-bromo-2'-deoxyuridine-5'-
monophosphate; CF, cystic fibrosis; CFTR, cystic fibrosis transmem-
brane conductance regulator; DS, donkey serum.
transduction of a gene encoding a normal version of the cystic
fibrosis transmembrane conductance regulator (CFTR) pro-
vided support for the feasibility of this approach (5, 6).
Rational development of somatic gene therapies for CF re-
quires a better understanding of the distribution of CF gene
expression in the human lung. Experience with the clinical
manifestations and pathologic consequences of CF strongly
suggests that the cells of the airway are directly involved in
pathogenesis (1). Several studies have supported this hypothe-
sis, including our recent characterization of normal human
bronchus, which localized CFTR RNA and protein to both the
surface epithelium and submucosal glands (6a). The surface
epithelium is affected by CF (7, 8) and has features that make it
an attractive but challenging target for direct gene transfer. It
may be possible to achieve efficient access ofgene transfer sub-
strates to the surface cells ofthe airway through relatively non-
invasive means such as aerosol inhalation or bronchial lavage.
However, the surface epithelium is a complex structure that
normally has a low level of cell cycling (9).
Several approaches for delivering genes to the airway have
been proposed including retroviruses (6, 10, 11), adenoviruses
(12), adeno-associated viruses (13, 14), and liposomes (15).
While each has its potential advantages, no single approach has
emerged as a method of choice for CF. The largest experience
in other models of gene therapy has been with retroviruses.
Many animal models (16) and all of the clinical applications
(17) of gene therapy to date are based on transplantation of
autologous cells modified ex vivo with retroviruses. More re-
cently, retroviruses have been used to directly introduce genes
into blood vessels and liver (18, 19). An important consider-
ation in the application of retroviruses to in vivo airway gene
transfer relates to the extensive experience with these reagents
in other models and their relative safety. Disadvantages include
relatively low viral titers and the presumed requirement for
active replication ofthe recipient cell to achieve gene transduc-
tion.
Critical to the development of effective gene therapies of
CF is the availability ofanimal models to evaluate the feasibil-
ity, efficacy, and safety of the various approaches. Epithelial
cells derived from the airway of a variety of animals have been
shown to develop into fully differentiated epithelia after they
are seeded onto denuded trachea and implanted into nu/nu
mice (20, 21). Our initial attempt at using the xenograft system
for studying gene transfer was based on the reconstitution of
denuded trachea with rat tracheal cells exposed to retroviruses
while in primary culture (10). Grafts seeded with the geneti-
cally modified cells developed a fully differentiated epithelium
with patches oftransgene expressing cells possibly representing
clonal outgrowth of retroviral transduced progenitor cells. We
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report in this study a xenograft animal model based on the
generation of a fully differentiated human epithelium in athy-
mic mice. This model was used to assess the potential ofretrovi-
ruses for delivering recombinant genes into the human airway.
Methods
Epithelial cell isolation and culture. Human bronchial tissue (three
different bronchial samples were analyzed) was obtained from healthy
donor lungs at the time of lung transplantation. Primary cultures were
prepared according to a previous protocol with modifications (22). The
tissue was soaked and rinsed in modified Eagle's medium containing
50 U/ml penicillin, 50 Ag/ml streptomycin, 40 Mg/ml tobramycin, 50
jig/ml ceftazidime, 2.5 jg/ml amphotericin B, 10 Mg/ml DNAse, and
0.5 mg/ml dithiothreitol for 4-12 h at 40C. The tissue was then trans-
ferred to the same medium supplemented with 0.1% protease- 14 and
incubated for an additional 30-34 h at 40C. FCS was then added to a
final concentration of 10%, and the cells were removed by agitation and
blunt scraping. Cells were pelleted and washed two times in Ham's F12
containing 10% FCS. Cells were resuspended in Ham's F12 hormon-
ally defined medium containing 1 MM hydrocortisone, 10 jg/ml insu-
lin, 30 nM thyroxine, 5 ;g/ml transferrin, 25 ng/ml epidermal growth
factor, 3.75 ,ug/ml endothelial cell growth supplement, 10 ng/ml chol-
era toxin, 50 U/ml penicillin, 50 ;g/ml streptomycin, 40 ,g/ml tobra-
mycin, 50 ug/ml ceftazidime, and 2.5 Ag/ml amphotericin B, and
plated at a density of 2 X 106 cells per 100-mm plate (uncoated plastic).
The medium on cultures was replaced every 24 h. Cultures were har-
vested on day 4 by treatment of 0.1% trypsin followed by the addition
of 10% FCS/Ham's F12. Cells were pelleted and resuspended in hor-
monally defined medium for seeding into denuded rat tracheas.
Establishment of xenografts. Donor rat tracheas were harvested
from CO2 asphyxiated male Fisher 344 rats (200-250 g) and denuded
by three rounds offreeze thawing followed by rinsing ofthe lumen with
modified Eagle's medium. Tracheas were ligated to tubing at both ends
after seeding of 2 x I04 or 2 x 106 primary bronchial epithelial cells in
30 ;d ofhormonally defined medium. These "open-ended" grafts were
then inplanted subcutaneously in the flanks of female nu/nu BALB/c
mice anesthetized by intraperitoneal injections of 100 mg/kg ketamine
and 20 mg/kg xylazine. Implants were sutured such that the ends ofthe
tubing exited through the back of the neck (Fig. 1 A). Grafts were
flushed weekly with Ham's F12 to remove excess mucus.
Analysis ofgrafts by electron microscope. Xenografts were excised
rinsed briefly in PBS followed by overnight fixation in 2.5% glutaralde-
hyde, 1.5% paraformaldehyde, 0.02% CaCl2 in 0.1 M sodium cacodyl-
ate (pH 7.4) at 4°C. After fixation, the tissue was washed repeatedly in
0.1 M sodium cacodylate, postfixed in 1% osmium tetroxide (1 h at
0°C), dehydrated in alcohols, and embedded in epoxy resins. Sections
were stained with uranyl acetate and lead citrate before being viewed
and photographed in an electron microscope (model 1 I a; Hitachi Sci.
Instrs., Mountain View, CA).
BrdU labeling and detection ofmitotically active cells. Mitotically
active cells were labeled at the time ofBAG retroviral infection by the
addition of 50 jg/ml 5-bromo-2'-deoxyuridine-5'-monophosphate
(BrdU) to the retroviral medium. Grafts seeded with 2 X 104 and 1
X 106 cells were labeled with BrdU at 1 and 4 wk after transplantation,
respectively. Infections were performed in the presence ofBrdU for 24
hrs after which the tracheas were flushed with 2 ml F12 medium fol-
lowed by expulsion of all fluid from the lumen of the graft with air.
Grafts were harvested 3 d after infection and fresh frozen in optimal
cutting temperature embeding compound. Sections (4-rm) were fixed
in methanol for 10 min at -20°C followed by air drying. Sections were
then treated with 2 N HC1 for 1 h at 37°C and neutralized in 0.1 M
NaBorate pH 8.5 for 10 min. After rinsing in PBS for 10 min, sections
were blocked in 20% donkey serum (DS)/PBS for 30 min. Mouse anti-
BrdU-FITC conjuagated monoclonal antibody (Boehringer Mann-
heim Corp., Indianapolis, IN) was incubated with the sections (50 Mg!
ml) in PBS containing 1.5% DS for 90 min at room temperature. Sec-
tions were washed in 1.5% DS/PBS and coverslipped in mounting
medium (Citifluor Inc., London, England). Colocalization oflacZ posi-
tive cells with BrdU label was not possible because ofHCI destruction
of anti-lacZ reactive epitopes.
The percent of BrdU labeling was calculated by counting 30,000
cells (as evident by nuclei under Nomarski optics) from 12 different
sections of two fully differentiated grafts and 3,000 cells from 12 sec-
tions of two regenerating grafts. The averages and standard deviations
of this analysis are reported in the text.
Localization of cell specific cytokeratins and CFTR. Fresh frozen
xenograft tissue was sectioned at 6 Mm onto poly(L-lysine)-coated slides
and fixed in acetone for 10 min at -20'C followed by air drying. Sec-
tions were blocked in 20% DS in PBS for 30 min followed by the
addition of the following primary antibodies for 90 min. CFTR was
localized by indirect double immunofluorescence using an affinity puri-
fied rabbit polyclonal antibody to a COOH-terminal peptide (residues
1468-1480) ofCFTR (23, 24, 25). This previously characterized anti-
body is designated a-1468 and shows reactivity in normal bronchial
epithelium in a subset of keratin-14 positive cells (6 a). Cytokeratin-14
(RCK107) and cytokeratin-18 (RGE53) monoclonal hybridoma su-
pernatants were kindly provided by Dr. Frans Ramekers University of
Limburg, Maastricht, The Netherlands and have been previously char-
acterized (26, 27). Hybridoma supernatants were used undiluted and
a- 1468 was used at a concentration of 5,g/ml. After primary antibody
incubation the sections were washed three times and incubated with 5
ttg/ml of FITC-anti-mouse or FITC-anti-rabbit for 30 min. Sections
were washed and coverslipped in mounting medium.
Peptide competition experiments were performed with a-1468 by
preincubating 0.5 mg/ml peptide (residues 1468-1480 of CFTR pro-
tein) with 0.25 mg/ml of a-1468 in PBS containing 1.5% DS overnight
at 4°C before immunofluorescent staining. Control uncompeted anti-
body was incubated under the same conditions but without peptide.
Production of virus and retroviral infection. Previously described
amphotropic packaging cell lines harboring the BAG lacZ containing
provirus (28) and low density lipo-protein receptor containing provirus
(29) were grown in DME containing 10% FCS and 1 Ag/ml penicillin/
streptomycin. In the BAG construct lacZ is expressed from the viral
long terminal repeat. Virus was harvested from a confluent monolayer
of cells by the addition of fresh medium for 18 h. After harvesting,
stocks were supplemented with 3 Ag/ml polybrene and passed through
0.2-,gm filters. Viral stocks were used fresh for direct infusion into xen-
ografts. Xenografts were exposed to 1 ml of retrovirus by slow infusion
for I h in all cases except for retroviral infection in the presence of
BrdU in which the lumen of the grafts were filled with virus and incu-
bated for 24 h. After infection, grafts were rinsed with 2 ml of Ham's
F12 followed by expulsion of all fluid from the graft with air.
Analysis ofgraftsfor expression oflacZ. Xenografts were cytochemi-
cally analyzed for lacZ transgene expression using a previously de-
scribed protocol (10). At various times after retroviral infections xeno-
grafts were excised from euthanized mice and directly fixed in 0.5%
glutaraldehyde/PBS for 10 min followed by rinsing in 1 mM MgClJ/
PBS for two 15-min washes. Xenograft rings were then stained in Xgal
solution (10) for 4 h. Tissue was then rinsed in PBS and postfixed in 4%
paraformaldehyde/PBS overnight before embedding in glycometha-
crylate by standard protocol.
Results and Discussion
Epithelial cells derived from main stem bronchi of donor or-
gans were plated in culture and subsequently harvested and
seeded onto denuded rat trachea that were implanted into nu/
nu mice. Several problems were encountered in our initial ex-
periments. When ligated at both ends, the implanted tracheas
accumulated increasing quantities ofmucus that eventually led
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Figure 1. Open-ended xenografts. (A) Xenografts were ligated to flexible plastic tubing and implanted subcutaneously. Implants were sutured
such that the ends of the tubing exited through the back of the neck. (B) Transmission electron micrograph of a fully differentiated bronchial
xenograft epithelium. Xenograft was seeded with 2 X 106 cells and allowed to develop for 3 wk. Ci, ciliated cell; G, goblet cell; and B, basal cell
(bar = 20 gm).
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to distortion ofthe graft. After 3-6 wk incubation, the reconsti-
tuted epithelium contained major areas of a squamous or cu-
boidal epithelium, as well as pseudostratified morphology. To
prevent the intraluminal accumulation of mucus and provide
easy access to the xenograft, we modified the system in the
following manner. The ends of the implanted tracheas were
kept open to the surface via plastic tubing that was tied to the
proximal and distal ports of the graft, tunneled subcutane-
ously, and exited percutaneously. Fig. 1 A illustrates this modifi-
cation. Xenografts established using this technique were irri-
gated regularly with isotonic buffer to prevent accumulation of
mucus. The resulting fully mature graft produced a pseudostrat-
ified epithelium along the entire surface of the the trachea that
was indistinguishable from that ofa normal bronchus. An elec-
tron micrograph of a typical xenograft is presented in Fig. 1 B.
All cell types were represented including a layer of basal cells,
ciliated cells, secretory goblet cells, and nonciliated columnar
cells. A more complete morphological description of the hu-
man xenograft system will be provided elsewhere.
The modified xenografts were used to study the biology of
retroviral-mediated gene transfer. Two different biological sub-
strates for gene transfer were established: grafts were seeded
with a low density of cells (2 x 104 cells) and maintained for
one week in the nu/nu mice to produce a regenerating epithe-
lium, or were seeded with a high density of cells (2 X 106 cells)
and maintained for 3 wk in the nu/nu mice to provide a fully
differentiated, relatively quiescent epithelium.
Analysis ofmorphology andproliferative activity ofregener-
ating and differentiated grafts. Light microscopic analysis of
grafts seeded at low density revealed relatively undifferentiated
morphology. Cells were either squamous or cuboidal in shape
and were frequently stratified into multiple layers. Approxi-
mately > 95% of the cells reacted with antibodies for the basal
cell specific marker keratin-14 (Fig. 2 A), while infrequent
squamous cells lining the lumen of this cuboidal epithelium
(< 2% of total cells) reacted with a cytokeratin- 18 antibody
(Fig. 2 B). None ofthe cells appeared to polarize, contain cilia,
or react to alcian blue or periodic acid-Schiff (data not shown).
When grafts seeded at low density were incubated with BrdU to
assess the overall state of cell proliferation at the time of retro-
viral infection, 40±4% of the cells were mitotically active (Fig.
3 A). These studies indicate that after 1 wk, grafts seeded with 2
x 104 cells contain an undifferentiated epithelium that is rap-
idly regenerating (subsequently referred to as regenerating
grafts). If left in the nu/nu mice for 6 wk, these grafts became
quiescent and fully differentiated (Fig. 5 B).
Grafts seeded at high density (2 X 106 cells) develop a fully
differentiated epithelium within 3 wk. The pattern of staining
seen in fully differentiated grafts with the basal cell specific
keratin- 14 antibody (Fig. 2 C) and the keratin- 18 antibody
(Fig. 2 D), which is specific for differentiated columnar cells,
was equivalent to the pattern of staining in normal human
bronchus (data not shown) and that reported in other species
such as rat (26, 27). In addition to characterizing the pattern of
cytokeratin staining, we felt it was important to compare the
localization ofCFTR in the fully differentiated graft to normal
human bronchus, since this xenograft system will be used as a
model for studying CF gene therapies. Fig. 2 E shows the pat-
tern of staining within a fully differentiated graft to a polyclo-
nal antibody made to the COOH terminus ofCFTR. This pat-
tern is virtually identical to that seen in normal human bron-
chial samples (6 a), and is competed by preincubation of the
antibody with peptide (Fig. 2 F). Low level staining is detected
on the apical surface ofcolumnar epithelial cells, while a higher
level of staining is seen in basal and intermediate cells. Incuba-
tion of these grafts with BrdU resulted in labeling of 1.1±0.2%
of the cells (Fig. 3 B), a number similar to that found in the
bronchi ofseveral types ofanimals including rat and mouse (9).
We conclude that after 3 wk, grafts seeded at high density pro-
duce an epithelium that closely resembles that of a normal,
unperturbed human main stem bronchus (subsequently re-
ferred to as differentiated grafts).
Analysis of retroviral gene expression in regenerating and
differentiated grafts. Regenerating grafts were exposed to lacZ
retrovirus and subsequently analyzed histochemically for retro-
viral gene expression. Analysis of grafts 3 d after infection re-
vealed lacZ expression in 5-10% of the reconstituted epithe-
lium (Figs. 4 A and 5 A). Expression oflacZ was demonstrated
in cells located throughout the depth of the apparently undif-
ferentiated stratified epithelium (Fig. 5 A). When these grafts
were allowed to develop into a fully differentiated epithelium
(42 d after exposure to virus) the pattern of Xgal staining
changed from frequent positive single cells to a limited number
of large aggregates oftransgene expressing cells with occasional
positive single cells. The total surface area ofthe differentiated
graft that was repopulated with lacZ expressing cells varied
from 1-5% between three different tissue samples analyzed.
This pattern of staining is compatible which clonal expansion
of retroviral transduced progenitor cells. Within these aggre-
gates, all cell types were found to express the transgene includ-
ing basal cells, goblet cells, ciliated cells, and nonciliated col-
umnar cells. The intensity of Xgal staining in undifferentiated
grafts appeared to diminish when compared with staining of
the same grafts allowed to differentiate for 42 d after infection.
This difference may be caused by variation in long terminal
repeat transcription effected by the differentiated state of the
epithelium. Experiments in which retroviruses were exposed to
fully differentiated epithelium produced dramatically different
results. Fully differentiated grafts exposed to lacZ retroviruses
failed to demonstrate any evidence for retroviral gene transfer
or expression based on the Xgal histochemical stain (Figs. 4 C
and 5 C).
These studies demonstrate the feasibility ofdirectly deliver-
ing recombinant genes to a human airway epithelium with ret-
roviruses. The efficiency of gene transfer into an undifferen-
tiated regenerating epithelium was only 5-10-fold less than
that achieved when the same virus was exposed to a rapidly
dividing culture of murine fibroblasts for 12 h (data not
shown). Importantly, the transgene continued to express for
the life of the xenograft (5 wk after exposure to virus) and was
distributed in all cell types (Figs. 4 B and 5 B). In contrast,
retroviral mediated gene transfer into a quiescent, fully differ-
entiated graft was remarkably inefficient (Figs. 4 C and 5 C).
This may be explained in part by the extremely low numbers of
dividing cells in these graft at the time ofexposure to virus. The
requirement of cell division for retroviral-mediated gene
transfer has been demonstrated in vitro using cultured diploid
fibroblasts (30). Other factors may have contributed to the low
efficiency of gene transfer in the differentiated grafts including
diminished expression of the receptor for the amphotropic
virus or localization of the receptor to inaccessible areas of the
cell such as intracellular compartments or the basolateral sur-
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Figure 4. Retroviral infection
into regenerating and fully
differentiated epithelium.
Micrographs show the lu-
minal surface of grafts seeded
with 2 x IO' cells, infected
with BAG retrovirus for I h,
and harvested 3 d (A) and 42
d (B) after infection followed
by cytochemical staining in
Xgal. (C) shows the luminal
surface of a graft seeded with
2 x 106 cells, infected with
BAG retrovirus for I h, and
harvested 3 d after infection
followed by cytochemical
staining in Xgal. No Xgal
staining was seen in BAG in-
fected fully differentiated
..:.S_~~~~ ~ ~ ~ ~ ~ ~ ~ ~ ~~~~~~~~~~~~~~gat havse 21date n
fection or in any grafts (re-
generating or fully differen-
tiated) infected with LDLR
retrovirus (data not shown).
Microphot-FXA Nikon mi-
croscope (bar = 300 pm).
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with BAG for 1 h at I wk
into a regenerating epithe-
lium harvested 3 d after in-
fection (A) and 42 d after in-
fection (B) and cytochemi-
cally stained in Xgal. (C)
shows retroviral infection
with BAG for I h at 3 wks
into a fully differentiated
graft harvested 3 d after in-
fection followed by cyto-
chemical staining in Xgal.
4-,m GMA sections were
counterstained in hematoxy-
lin and visualized under No-
marski optics using a Micro-
phot-FXA Nikon microscope
(bar = 60gim).




















face. It is impossible to study these potential mechanisms be-
cause the amphotropic virus receptor has not been identified.
The important challenge is to translate these observations
in the xenografts to practical approaches of gene transfer into
the airway in vivo. These data strongly suggest that it will be
necessary to significantly perturb the biology of the airway in
order to achieve significant levels ofgene transfer. Various mod-
els ofairway injury have been described which lead to compen-
satory increases in the proliferation of various cell types of the
upper airway including basal cells and various secretory cells
(9). These usually involve transient exposure to noxious stim-
uli such as toxic chemicals, mechanical irritation, or viral path-
ogens. The clinical feasibility of these interventions remains to
be demonstrated. Alternatively, it may be possible to deliver
genes via retroviruses to the undifferentiated epithelium of fe-
tuses in utero, circumventing the need for airway injury in the
adult. The relevance of the regenerating graft to models of air-
way injury and the feasibility ofaccomplishing gene transfer in
an endogenous airway must await additional studies in ani-
mals. In addition, it is not clear ifthe efficiency ofgene transfer
accomplished in the undifferentiated graft (i.e., 5-10%) would
be sufficient to achieve a therapeutic effect. Boucher et al. (31 )
have achieved significant functional correction in a polarized
monolayer of CF cells when only 10% of the cells have been
corrected by gene transfer.
In summary we describe an animal model for evaluating
the feasibility and potential efficacy of somatic gene therapies
for CF. Our results support the use ofrecombinent retroviruses
in these therapies ifthe recipient airway epithelium is relatively
undifferentiated and rapidly regenerating.
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